| Features | |
| Active substance | Zolmitriptan |
| Also known as | Zomig |
| Blood pressure | May cause transient increase |
| Chemical name | (4S)-4-[[3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl]methyl]-2-oxazolidinone |
| Dosage (medical) | 2.5 mg to 5 mg taken orally at onset of migraine, may repeat after 2 hours if necessary, maximum 10 mg per day |
| Dosage (sports) | Not applicable |
| Effects | Relief of migraine symptoms |
| Formula | C16H21N3O2 |
| Half-life | 2.5 to 3 hours |
| Hepatotoxicity | Low |
| Lab Test | Not specific to zolmitriptan |
| Main action | Serotonin receptor agonist |
| Side effects | Dizziness, neck/throat/jaw pain, nausea, dry mouth, tiredness |
| Storage conditions | Store at room temperature between 20В°C to 25В°C (68В°F to 77В°F) |
| Strength | 5mg |
| Substance class | Triptan |
| Trade name | Zomig |
| Use in sports | None |
| Water Retention | None |
| Manufacturer | Cipla Ltd. |
| Packing | 1 bottle/pack |